Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Adamis Pharma Acquires US Compounding | Contract Pharma

What are you searching for?

Sign in
Breaking News

Adamis Pharma Acquires US Compounding

US Compounding will become a wholly-owned subsidiary of Adamis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adamis Pharmaceuticals has acquired US Compounding, a privately held company registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act (FD&C Act), that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the U.S. US Compounding will become a wholly-owned subsidiary of Adamis.

“USC will be a compelling addition for Adamis. We believe the combination of revenues of $20 million or greater in each of the last two years, a large sales and marketing team and robust manufacturing capabilities, will be both synergistic with and accretive to Adamis’ overall value,” said Dennis Carlo, president and chief executive officer, Adamis. “We expect the new division will generate at least $5 million in operating income over the first 12 months and achieve an annualized run rate of $50 million per year within 24 months after closing.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics